Cited by 1,001Lipoproteins and Cardiovascular HealthCardiac and Coronary Surgery TechniquesCholesterol and Lipid Metabolism

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Effect of Partial Ileal Bypass Surgery on Mortality and Morbidity from Coronary Heart Disease in Patients with Hypercholesterolemia: Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

Open access

Buchwald, Henry, Varco, Richard L., Matts, John P., Long, John M., Fitch, Laurie L., Campbell, Gilbert S., Pearce, Malcolm B., Yellin, Albert E., Edmiston, W. Allan, Smink, Robert D., Sawin, Henry S., Campos, Christian T., Hansen, Betty J., Tuna, Naip, Karnegis, James N., Sanmarco, Miguel E., Amplatz, Kurt, Castaneda-Zuniga, Wilfredo R., Hunter, David W., Bissett, Joseph K., Weber, Frederic J., Stevenson, James W., Leon, Arthur S., Chalmers, Thomas C.·1990·New England Journal of Medicine

DOI 10.1056/nejm199010043231404

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND AND METHODS: The Program on the Surgical Control of the Hyperlipidemias (POSCH), a randomized clinical trial, was designed to test whether cholesterol lowering induced by the partial ileal bypass operation would favorably affect overall mortality or mortality due to coronary heart disease. The study population consisted of 838 patients (417 in the control group and 421 in the surgery group), both men (90.7 percent) and women, with an average age of 51 years, who had survived a first myocardial infarction. The mean follow-up period was 9.7 years. RESULTS: When compared with the control group at five years, the surgery group had a total plasma cholesterol level 23.3 percent lower (4.71 +/- 0.91 vs. 6.14 +/- 0.89 mmol per liter [mean +/- SD]; P less than 0.0001), a low-density lipoprotein cholesterol level 37.7 percent lower (2.68 +/- 0.78 vs. 4.30 +/- 0.89 mmol per liter; P less than 0.0001), and a high-density lipoprotein cholesterol level 4.3 percent higher (1.08 +/- 0.26 vs. 1.04 +/- 0.25 mmol per liter; P = 0.02). Overall mortality and mortality due to coronary heart disease were reduced, but not significantly so (deaths overall [control vs. surgery], 62 vs. 49, P = 0.164; deaths due to coronary disease, 44 vs. 32, P = 0.113). The overall mortality in the surgery subgroup with an ejection fraction greater than or equal to 50 percent was 36 percent lower (control vs. surgery, 39 vs. 24; P = 0.021). The value for two end points combined--death due to coronary heart disease and confirmed nonfatal myocardial infarction--was 35 percent lower in the surgery group (125 vs. 82 events; P less than 0.001). During follow-up, 137 control-group and 52 surgery-group patients underwent coronary-artery bypass grafting (P less than 0.0001). A comparison of base-line coronary arteriograms with those obtained at 3, 5, 7, and 10 years consistently showed less disease progression in the surgery group (P less than 0.001). The most common side effect of partial ileal bypass was diarrhea; others included occasional kidney stones, gallstones, and intestinal obstruction. CONCLUSIONS: Partial ileal bypass produces sustained improvement in the blood lipid patterns of patients who have had a myocardial infarction and reduces their subsequent morbidity due to coronary heart disease. The role of this procedure in the management of hypercholesterolemia remains to be determined. These results provide strong evidence supporting the beneficial effects of lipid modification in the reduction of atherosclerosis progression.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199010043231404

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Practical Nonparametric Statistics
Groggel, D. J., & Conover, W. J. (2000) · Technometrics · doi:10.2307/1271101 · Cited by 11,076
Immunochemical quantitation of antigens by single radial immunodiffusion
Mancini, G., Carbonara, A. O., & Heremans, J. F. (1965) · Immunochemistry · doi:10.1016/0019-2791(65)90004-2 · Cited by 9,091
Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
A Generalized Wilcoxon Test for Comparing Arbitrarily Singly-Censored Samples
Gehan, E. A. (1965) · Biometrika · doi:10.1093/biomet/52.1-2.203 · Cited by 3,407
The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease
(1984) · JAMA · doi:10.1001/jama.1984.03340270029025 · Cited by 2,747
Incidence of Coronary Heart Disease and Lipoprotein Cholesterol Levels
Castelli, W. P. (1986) · JAMA · doi:10.1001/jama.256.20.2835 · Cited by 2,512
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study.
Kannel, W., Castelli, W., Gordon, T., & McNamara, P. M. (2020) · Annals of Internal Medicine · doi:10.7326/0003-4819-74-1-1 · Cited by 2,160

Show all 58 references

Research works printed but not linked: 29

10.1001/jama.256.20.2823 · DOI · Paper page
Leren, 1966, Acta Med Scand Suppl, 466, 1
1968, Lancet, 2, 693
Frantz, 1975, Circulation, 52, II-4
10.1001/jama.231.4.360 · DOI
10.1001/jama.251.3.351 · DOI · Paper page
10.1001/jama.257.23.3233 · DOI
Buchwald H. Intestinal bypass for hypercholesterolemia. In: Nyhus LM, Baker RJ, eds. Mastery of surgery. Vol. 3. Boston: Little, Brown, 1984:901–7.
Buchwald H, Campos CT. Partial ileal bypass for control of hyperlipidemia and atherosclerosis. In: Sabiston DC Jr, Spencer FC, eds. Surgery of the chest. 5th ed. Philadelphia: W.B. Saunders, 1990:1799–819.
Schouten, 1986, Artery, 13, 240
1959, Stat Bull Metrop Life Insur Co, 40, 1
Bruce, 1971, Ann Clin Res, 3, 323
National Heart and Lung Institute, Lipid Research Clinics Program. Manual of laboratory operations. Vol. 1. Bethesda, Md.: National Institutes of Health, 1974. (DHEW publication no. (NIH) 75–628.)
1970, Bull World Health Organ, 43, 891
Mantel, 1966, Cancer Chemother Rep, 50, 163
Matts, Controlled Clin Trials
Campos, 1987, Surgery, 102, 424
Campos, 1988, Curr Surg, 45, 380
Campos, 1988, Surg Forum, 39, 193
Addison, 1851, Guys Hosp Rep, 2, 267
Ignatovski, 1908, Izviest Imp Voyenno-med Akad S Petersb, 16, 154
Anitschkow, 1913, Centralbl Allg Pathol Pathol Anat, 24, 1
Wacker, 1913, Münchener Med Wochenschr, 60, 2097
European Coronary Surgery Study Group, 1982, Lancet, 2, 1173
Buchwald, 1965, Surgery, 58, 22
Scott, 1967, Surg Gynecol Obstet, 125, 3
Buchwald, 1963, Circulation, 28, II-649
Moore, 1969, Surgery, 65, 98
Buchwald, Ann Surg

Sorted by citations

Bariatric Surgery: A Systematic Review and Meta-analysis
Buchwald, H., Avidor, Y., Braunwald, E., Jensen, M. D., Pories, W., Fahrbach, K., & Schoelles, K. (2004) · JAMA · doi:10.1001/jama.292.14.1724 · Cited by 6,800
Self-citation
Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
Epstein, F. H., Fuster, V., Badimón, L., Badimón, L., & Chesebro, J. H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201303260506 · Cited by 3,792
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Sever, P., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M. J., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,790
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
Pedersen, T. R. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.027 · Cited by 3,098
PLEIOTROPIC EFFECTS OF STATINS
Liao, J. K., & Laufs, U. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095748 · Cited by 1,994
Upregulation of Endothelial Nitric Oxide Synthase by HMG CoA Reductase Inhibitors
Laufs, U., Fata, V. L., Plutzky, J., & Liao, J. K. (1998) · Circulation · doi:10.1161/01.cir.97.12.1129 · Cited by 1,837
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Silverman, M. G., Ference, B. A., Im, K., Wiviott, S. D., Giugliano, R. P., Grundy, S. M., Braunwald, E., & Sabatine, M. S. (2016) · JAMA · doi:10.1001/jama.2016.13985 · Cited by 1,483
Pleiotropic Effects of Statins on the Cardiovascular System
Oesterle, A., Laufs, U., & Liao, J. K. (2017) · Circulation Research · doi:10.1161/circresaha.116.308537 · Cited by 1,247
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800742 · Cited by 1,241
Current Perspectives on Statins
Maron, D. J., Fazio, S., & Linton, M. F. (2000) · Circulation · doi:10.1161/01.cir.101.2.207 · Cited by 1,216
By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?
Law, M., Wald, N., & Thompson, S. (1994) · British medical journal · doi:10.1136/bmj.308.6925.367 · Cited by 1,306
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
Endres, M., Laufs, U., Huang, Z., Nakamura, T., Huang, P. L., Moskowitz, M. A., & Liao, J. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8880 · Cited by 957
Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women
Mosca, L. J., Appel, L. J., Benjamin, E. J., Berra, K. A., Chandra‐Strobos, N., Fabunmi, R. P., Grady, D. G., Haan, C. K., Hayes, S. N., Judelson, D. R., et al. (2004) · Circulation · doi:10.1161/01.cir.0000114834.85476.81 · Cited by 918
Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP)
Haskell, W. L., Alderman, E. L., Fair, J. M., Maron, D. J., Mackey, S. F., Superko, H. R., Williams, P. T., Johnstone, I. M., Champagne, M. A., & Krauss, R. M. (1994) · Circulation · doi:10.1161/01.cir.89.3.975 · Cited by 884
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
Jukema, J., Bruschke, A. V., van Boven, A. J., Reiber, J., Bal, E., Zwinderman, A., Jansen, H., Boerma, G., van Rappard, F. M., & Kong, L. I. (1995) · Circulation · doi:10.1161/01.cir.91.10.2528 · Cited by 911
Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease.
Brown, B. G., Zhao, X., Sacco, D., & Albers, J. J. (1993) · Circulation · doi:10.1161/01.cir.87.6.1781 · Cited by 813
New insights into the pharmacodynamic and pharmacokinetic properties of statins
Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., & Bernini, F. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00045-5 · Cited by 796
Influence of Pravastatin and Plasma Lipids on Clinical Events in the West of Scotland Coronary Prevention Study (WOSCOPS)
(1998) · Circulation · doi:10.1161/01.cir.97.15.1440 · Cited by 792
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784
Cardiovascular Disease in Women
Mosca, L. J., Manson, J. E., Sutherland, S. E., Langer, R. D., Manolio, T. A., & Barrett-Connor, E. L. (1997) · Circulation · doi:10.1161/01.cir.96.7.2468 · Cited by 733
Report of the Conference on Low Blood Cholesterol: Mortality Associations.
Jacobs, D. R., Blackburn, H., HIGGINS, M. W., REED, D. M., Iso, H., McMillan, G. C., Neaton, J. D., Nelson, J., Potter, J., & Rifkind, B. M. (1992) · Circulation · doi:10.1161/01.cir.86.3.1046 · Cited by 720
Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)
Musso, G., Gambino, R. J., & Cassader, M. (2008) · Progress in Lipid Research · doi:10.1016/j.plipres.2008.08.001 · Cited by 691
Cholesterol Reduction in Cardiovascular Disease — Clinical Benefits and Possible Mechanisms
Levine, G. N., Keaney, J. F., & Vita, J. A. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502233320807 · Cited by 673
Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)
Watts, G. F., Lewis, B., Lewis, E. S., Coltart, D. J., Smith, L. D. R., Swan, A. V., Brunt, J. N. H., & Mann, J. I. (1992) · The Lancet · doi:10.1016/0140-6736(92)90863-x · Cited by 843
Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)
MAAS Investigators (1994) · The Lancet · doi:10.1016/s0140-6736(94)92082-6 · Cited by 644
Pleiotropic effects of statin therapy: molecular mechanisms and clinical results
Wang, C., Liu, P., & Liao, J. K. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.11.004 · Cited by 599
Effects of exercise and diet on chronic disease
Roberts, C. K., & Barnard, R. J. (2005) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00852.2004 · Cited by 556
Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial???Lipid Lowering Arm (ASCOT-LLA)
Sever, P., Dahl??f, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M. J., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2004) · Drugs · doi:10.2165/00003495-200464002-00005 · Cited by 525
The Farnesoid X Receptor
Claudel, T., Staels, B., & Kuipers, F. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000178994.21828.a7 · Cited by 506
Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.
Waters, D., Higginson, L., Gladstone, P., Kimball, B., May, M. L. L., Boccuzzi, S., & Lésperance, J. (1994) · Circulation · doi:10.1161/01.cir.89.3.959 · Cited by 512
Cholesterol Reduction With Atorvastatin Improves Walking Distance in Patients With Peripheral Arterial Disease
Mohler, E. R., Hiatt, W. R., & Creager, M. A. (2003) · Circulation · doi:10.1161/01.cir.0000090686.57897.f5 · Cited by 475
Effect of Simvastatin on Ischemic Signs and Symptoms in the Scandinavian Simvastatin Survival Study (4S)
Pedersen, T. R., KJEKSHUS, J. K., Pyörälà, K., OLSSON, A. G., Cook, T. J., Musliner, T. A., Tobert, J. A., & Haghfelt, T. H. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00904-1 · Cited by 465
The Epidemiology of Peripheral Arterial Disease: Importance of Identifying the Population at Risk
Criqui, M. H., Denenberg, J. O., Langer, R. D., & Fronek, A. S. (1997) · Vascular Medicine · doi:10.1177/1358863x9700200310 · Cited by 444
Cholesterol Reduction Yields Clinical Benefit: Impact of Statin Trials
Gould, A. L., Rossouw, J. E., Santanello, N. C., Heyse, J. F., & Furberg, C. D. (1998) · Circulation · doi:10.1161/01.cir.97.10.946 · Cited by 442
Hyperlipidemia and Coronary Disease
Lacoste, L., Lam, J. Y. T., Hung, J., Letchacovski, G., Solymoss, B., & Waters, D. D. (1995) · Circulation · doi:10.1161/01.cir.92.11.3172 · Cited by 444
Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events
Pitt, B., Mancini, G. B. J., Ellis, S. G., Rosman, H., Park, J.-S., & Mcgovern, M. E. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00301-0 · Cited by 424
Cholesterol lowering and mortality: the importance of considering initial level of risk.
Smith, G. D., Song, F., & Sheldon, T. (1993) · BMJ · doi:10.1136/bmj.306.6889.1367 · Cited by 420
HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis
Bustos, C., Hernández-Presa, M. Á., Ortego, M., Tuñón, J., Ortega, L. M., Pérez, F., Díaz, C., Hernández, G., & Egido, J. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00487-2 · Cited by 417
Bile Acids and Metabolic Regulation
Staels, B., & Fonseca, V. A. (2009) · Diabetes Care · doi:10.2337/dc09-s355 · Cited by 451
Atherosclerotic Vascular Disease Conference
Faxon, D. P., Fuster, V., Libby, P., Beckman, J. A., Hiatt, W. R., Thompson, R. W., Topper, J. N., Annex, B. H., Rundback, J. H., Fabunmi, R. P., et al. (2004) · Circulation · doi:10.1161/01.cir.0000128520.37674.ef · Cited by 421
Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?
Robinson, J. G., Smith, B., Maheshwari, N., & Schrott, H. G. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.05.085 · Cited by 409
Bile acid transporters and regulatory nuclear receptors in the liver and beyond
Halilbasic, E., Claudel, T., & Trauner, M. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.08.002 · Cited by 415
Prevention of the Angiographic Progression of Coronary and Vein-Graft Atherosclerosis by Gemfibrozil After Coronary Bypass Surgery in Men With Low Levels of HDL Cholesterol
Frick, M. H., Syvänne, M., Nieminen, M. S., Kauma, H., Majahalme, S. K., Virtanen, V., Kesäniemi, Y. A., Pasternack, A. I., & Taskinen, M. (1997) · Circulation · doi:10.1161/01.cir.96.7.2137 · Cited by 389
Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound.
Blankenhorn, D. H., Selzer, R. H., Crawford, D. W., Barth, J. D., Liu, C. R., Liu, C. H., Mack, W. J., & Alaupovic, P. (1993) · Circulation · doi:10.1161/01.cir.88.1.20 · Cited by 381
Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2).
Oelkers, P. M., Kirby, L. C., Heubi, J. E., & Dawson, P. A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119355 · Cited by 379
Meta-Analysis of the Relationship Between Non–High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk
Robinson, J. G., Wang, S., Smith, B. J., & Jacobson, T. A. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.024 · Cited by 368
Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes
Ray, K. K., Cannon, C. P., McCabe, C. H., Cairns, R., Tonkin, A. M., Sacks, F. M., Jackson, G., & Braunwald, E. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.03.077 · Cited by 356
Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73)
Ramsden, C. E., Zamora, D., Majchrzak‐Hong, S. F., Faurot, K. R., Broste, S. K., Frantz, R. P., Davis, J. M., Ringel, A., Suchindran, C., & Hibbeln, J. R. (2016) · BMJ · doi:10.1136/bmj.i1246 · Cited by 373
Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography.
Dayanikli, F., Grambow, D. W., Muzik, O., Mosca, L. J., Rubenfire, M., & Schwaiger, M. (1994) · Circulation · doi:10.1161/01.cir.90.2.808 · Cited by 355
Pravastatin Has Cholesterol-Lowering Independent Effects on the Artery Wall of Atherosclerotic Monkeys
Williams, J. K., Sukhova, G. K., Herrington, D. M., & Libby, P. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00537-8 · Cited by 347
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women
Mosca, L. J., Appel, L. J., Benjamin, E. J., Berra, K. A., Chandra‐Strobos, N., Fabunmi, R. P., Grady, D. G., Haan, C. K., Hayes, S. N., Judelson, D. R., et al. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000114834.85476.81 · Cited by 342
Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium.
Gould, K. L., Martucci, J., Goldberg, D., Hess, M. J., Edens, R. P., Latifi, R., & Dudrick, S. J. (1994) · Circulation · doi:10.1161/01.cir.89.4.1530 · Cited by 337
Prevention of coronary heart disease in clinical practice: recommendations of the task force of the European Society of cardiology, European atherosclerosis Society and European society of Hypertension
Pyörälä, K., DeBacker, G., Graham, I. D., Poole-Wilson, P. A., & Wood, D. A. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)90200-3 · Cited by 329
Changes in Myocardial Perfusion Abnormalities by Positron Emission Tomography After Long-term, Intense Risk Factor Modification
Gould, K. L. (1995) · JAMA · doi:10.1001/jama.1995.03530110056036 · Cited by 326
Lowering of serum cholesterol in hypercholesterolemic humans by tocotrienols (palmvitee)
Qureshi, A. A., Qureshi, N., Wright, J. J. K., Shen, Z., Kramer, G., GAPOR, A., Chong, Y. H., DeWitt, G. R., Ong, A. S. H., Peterson, D. M., et al. (1991) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/53.4.1021s · Cited by 315
Dyslipidaemia
Durrington, P. N. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14234-1 · Cited by 316
Clinical Utility of Bile Acid Sequestrants in the Treatment of Dyslipidemia: A Scientific Review
Insull, W. (2006) · Southern Medical Journal · doi:10.1097/01.smj.0000208120.73327.db · Cited by 308
Statins for the primary prevention of cardiovascular disease
Taylor, F. C., Ward, K. J., Moore, T. H., Burke, M., Smith, G. D., Casas, J. P., & Ebrahim, S. B. J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub4 · Cited by 315
Effects of Statins on 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition Beyond Low-Density Lipoprotein Cholesterol
Liao, J. K. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.009 · Cited by 310
Relation of vessel wall shear stress to atherosclerosis progression in human coronary arteries.
Gibson, C. M., Diaz, L., Kandarpa, K., Sacks, F. M., Pasternak, R. C., Sándor, T., Feldman, C. L., & Stone, P. H. (1993) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.13.2.310 · Cited by 309
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes
Cannon, C. P., Giugliano, R. P., Blazing, M. A., Harrington, R. A., Peterson, J. L., Sisk, C. M., Strony, J. T., Musliner, T. A., McCabe, C. H., Veltri, E. P., et al. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.07.023 · Cited by 294
Indications for Surgery for Obesity and Weight-Related Diseases: Position Statements from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)
De Luca, M., Angrisani, L., Himpens, J., Busetto, L., Scopinaro, N., Weiner, R., Sartori, A., Stier, C., Lakdawala, M., Bhasker, A. G., et al. (2016) · Obesity Surgery · doi:10.1007/s11695-016-2271-4 · Cited by 296
Self-citation
Exploiting the Vascular Protective Effects of High-Density Lipoprotein and its Apolipoproteins
Shah, P. K., Kaul, S., Nilsson, J. Å., & Cercek, B. (2001) · Circulation · doi:10.1161/hc4501.098468 · Cited by 298
Ezetimibe therapy: mechanism of action and clinical update
Toth, P. P., Phan, B. A. P., & Dayspring, T. D. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s33664 · Cited by 312
Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy
Zhou, Q., & Liao, J. K. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787315684 · Cited by 301
Lack of Effect of Lovastatin on Restenosis after Coronary Angioplasty
Weintraub, W., Boccuzzi, S. J., Klein, J. L., Kosinski, A. S., King, S. B., Ivanhoe, R. J., Cedarholm, J. C., Stillabower, M. E., Talley, J. D., DeMaio, S. J., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312002 · Cited by 291
Pharmacology of competitive inhibitors of HMg-CoA reductase
Corsini, A. (1995) · Pharmacological Research · doi:10.1016/1043-6618(95)80042-5 · Cited by 275
Prognostic significance of progression of coronary atherosclerosis.
Waters, D. D., Craven, T., & Lespérance, J. (1993) · Circulation · doi:10.1161/01.cir.87.4.1067 · Cited by 294
Cholesterol Reduction Yields Clinical Benefit: A New Look at Old Data
Gould, A. L., Rossouw, J. E., Santanello, N. C., Heyse, J. F., & Furberg, C. D. (1995) · Circulation · doi:10.1161/01.cir.91.8.2274 · Cited by 272
Progress in predicting human ADME parameters in silico
Ekins, S., Waller, C. L., Swaan, P. W., Cruciani, G., Wrighton, S. A., & Wikel, J. H. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00109-x · Cited by 275
III Diretrizes Brasileiras Sobre Dislipidemias e Diretriz de Prevenção da Aterosclerose do Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia
Santos, R. D. (2001) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2001001500001 · Cited by 264
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression
Claudel, T., Inoue, Y., Barbier, O., Durán-Sandoval, D., Kosykh, V., Fruchart, J., Fruchart, J., Gonzalez, F. J., & Staels, B. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00896-5 · Cited by 279
Evidence for a New Pathophysiological Mechanism for Coronary Artery Disease Regression: Hepatic Lipase–Mediated Changes in LDL Density
Zambon, A., Hokanson, J. E., Brown, B. G., & Brunzell, J. D. (1999) · Circulation · doi:10.1161/01.cir.99.15.1959 · Cited by 263
Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis.
Zeiher, A. M., Schächlinger, V., Hohnloser, S. H., Saurbier, B., & Just, H. (1994) · Circulation · doi:10.1161/01.cir.89.6.2525 · Cited by 258
Effects of Lowering Average or Below-Average Cholesterol Levels on the Progression of Carotid Atherosclerosis Results of the LIPID Atherosclerosis Substudy
MacMahon, S., Sharpe, N., Gamble, G., Hart, H., Scott, J., Simes, J., & White, H. (1998) · Circulation · doi:10.1161/01.cir.97.18.1784 · Cited by 254
Liver Receptor Homologue-1 Mediates Species- and Cell Line-specific Bile Acid-dependent Negative Feedback Regulation of the Apical Sodium-dependent Bile Acid Transporter
Chen, F., Ma, L., Dawson, P. A., Sinal, C. J., Sehayek, E., Gonzalez, F. J., Breslow, J. L., Ananthanarayanan, M., & Shneider, B. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207903200 · Cited by 253
Avoiding revascularization with lifestyle changes: the multicenter lifestyle demonstration project
Ornish, D. M. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00744-9 · Cited by 234
Bile acid-induced negative feedback regulation of the human ileal bile acid transporter
Neimark, E., Chen, F., Li, X., & Shneider, B. L. (2004) · Hepatology · doi:10.1002/hep.20295 · Cited by 234
Effect of pravastatin on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) trial
Lewis, S. J., Sacks, F. M., Mitchell, J. S., East, C. A., Glasser, S. P., Kell, S., Letterer, R. A., Limacher, M. C., Moyé, L. A., Rouleau, J. L., et al. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00202-2 · Cited by 232
Effect of HMGcoA Reductase Inhibitors on Stroke
Bucher, H. C., Griffith, L. E., & Guyatt, G. H. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-2-199801150-00002 · Cited by 229
Role of the Intestinal Bile Acid Transporters in Bile Acid and Drug Disposition
Dawson, P. A. (2010) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-14541-4_4 · Cited by 227
George Lyman Duff Memorial Lecture. Arterial imaging and atherosclerosis reversal.
Blankenhorn, D. H., & Hodis, H. (1994) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.14.2.177 · Cited by 226
Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins
Shah, P. K., Kaul, S., Nilsson, J. Å., & Cercek, B. (2001) · Circulation · doi:10.1161/hc4401.098467 · Cited by 223
Effect of Cholesterol Reduction on Myocardial Ischemia in Patients With Coronary Disease
Andrews, T. C., Raby, K. E., Barry, J., Naimi, C., Allred, E. N., Ganz, P., & Selwyn, A. P. (1997) · Circulation · doi:10.1161/01.cir.95.2.324 · Cited by 220
Progression of Coronary Artery Disease Predicts Clinical Coronary Events
Azen, S. P., Mack, W. J., Cashin-Hemphill, L., LABREE, L. D., Shircore, A. M., Selzer, R. H., Blankenhorn, D. H., & Hodis, H. N. (1996) · Circulation · doi:10.1161/01.cir.93.1.34 · Cited by 215
Systematic Review on the Risk and Benefit of Different Cholesterol-Lowering Interventions
Bucher, H. C., Griffith, L. E., & Guyatt, G. H. (1999) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.19.2.187 · Cited by 211
Cost and health implications of cholesterol lowering.
Goldman, L., Gordon, D. J., Rifkind, B. M., Hulley, S. B., Detsky, A. S., Goodman, D. W., Kinosian, B. P., & Weinstein, M. C. (1992) · Circulation · doi:10.1161/01.cir.85.5.1960 · Cited by 209
Cardiovascular Effects of Estrogen and Lipid-Lowering Therapies in Postmenopausal Women
Guetta, V., & Cannon, R. O. (1996) · Circulation · doi:10.1161/01.cir.93.10.1928 · Cited by 207
Serum Cholesterol as a Prognostic Factor after Myocardial Infarction: The Framingham Study
Wong, N. D., Wilson, P. W. F., & Kannel, W. B. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-9-687 · Cited by 192
Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients
Sacks, F. M., Pasternak, R. C., Gibson, C. M., ROSNER, B. A., & Stone, P. H. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90506-1 · Cited by 186
Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias.
FODOR, J. G., Frohlich, J., Genest, J. J., & McPherson, P. R. (2000) · Europe PMC (PubMed Central) · Cited by 185
Quantitative coronary angiography to measure progression and regression of coronary atherosclerosis. Value, limitations, and implications for clinical trials.
de Feyter, P. D., Serruys, P., Davies, M. J., Richardson, P., Lubsen, J., & Oliver, M. (1991) · Circulation · doi:10.1161/01.cir.84.1.412 · Cited by 209
Pleiotropic effects of statins
Vasnawala, H., Kavalipati, N., Shah, J., & Ramakrishan, A. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.163106 · Cited by 189
Bile acids and their receptors
Martinot, E., Sèdes, L., Baptissart, M., Lobaccaro, J.-M., Caira, F., Beaudoin, C., & Volle, D. H. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.01.006 · Cited by 162
Long-term mortality after 5-year multifactorial primary prevention of cardiovascular diseases in middle-aged men.
Strandberg, T. E., Salomaa, V. V., Naukkarinen, V., Vanhanen, H. T., Sarna, S. J., & Miettinen, T. A. (1991) · PubMed · Cited by 179
Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management.
Superko, H. R., & Krauss, R. M. (1994) · Circulation · doi:10.1161/01.cir.90.2.1056 · Cited by 176

Authors: Buchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., Sawin, H. S., Campos, C. T., Hansen, B. J., Tuna, N., Karnegis, J. N., Sanmarco, M. E., Amplatz, K., Castaneda-Zuniga, W. R., Hunter, D. W., Bissett, J. K., Weber, F. J., Stevenson, J. W., Leon, A. S., & Chalmers, T. C.
Affiliations: University of Minnesota (US)
University of Southern California (US)
ORCID: Long, John M.
Hunter, David W.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1990-10-04
Volume: 323
Issue: 14
Pages: 946-955
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199010043231404
OpenAlex: W2331959986
Cited by: 1,001
References: 58
Citations by year: 2026: 3 · 2025: 2 · 2024: 3 · 2023: 9 · 2022: 5 · 2021: 20 · 2020: 11 · 2019: 16 · 2018: 10 · 2017: 11 · 2016: 22 · 2015: 15 · 2014: 17 · 2013: 12 · 2012: 17
FWCI: 84.71
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Surgery › Cardiac and Coronary Surgery Techniques
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords: partial ileal bypass, hypercholesterolemia, coronary artery disease, mortality, myocardial infarction, cholesterol lowering, LDL cholesterol, HDL cholesterol, first myocardial infarction, coronary artery bypass grafting, ejection fraction, long-term outcomes, nonfatal myocardial infarction
MeSH terms: Adult, Coronary Disease, Electrocardiography, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Hyperlipidemias, Jejunoileal Bypass, Lipids, Male, Middle Aged, Ultrasonography, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Coronary Angiography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of Partial Ileal Bypass Surgery on Mortality and Morbidity from Coronary Heart Disease in Patients with Hypercholesterolemia: Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks